MA41496A - Compositions pharmaceutiques comprenant la n-(3,5-diméthoxyphényl)-n'-(1-méthyléthyl)-n-[3-(1-méthyl-1h-pyrazol-4-yl)quinoxalin-6-yl]éthane-1,2-diamine - Google Patents

Compositions pharmaceutiques comprenant la n-(3,5-diméthoxyphényl)-n'-(1-méthyléthyl)-n-[3-(1-méthyl-1h-pyrazol-4-yl)quinoxalin-6-yl]éthane-1,2-diamine

Info

Publication number
MA41496A
MA41496A MA041496A MA41496A MA41496A MA 41496 A MA41496 A MA 41496A MA 041496 A MA041496 A MA 041496A MA 41496 A MA41496 A MA 41496A MA 41496 A MA41496 A MA 41496A
Authority
MA
Morocco
Prior art keywords
quinoxalin
dimethoxyphenyl
pyrazol
methylethyl
ethane
Prior art date
Application number
MA041496A
Other languages
English (en)
Other versions
MA41496B1 (fr
Inventor
Diego Fernando Domenico Broggini
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55442769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41496(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of MA41496A publication Critical patent/MA41496A/fr
Publication of MA41496B1 publication Critical patent/MA41496B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
    • C09K15/20—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen
MA41496A 2015-02-10 2016-02-09 Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine MA41496B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15154554 2015-02-10
EP15188982 2015-10-08

Publications (2)

Publication Number Publication Date
MA41496A true MA41496A (fr) 2017-12-19
MA41496B1 MA41496B1 (fr) 2021-09-30

Family

ID=55442769

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41496A MA41496B1 (fr) 2015-02-10 2016-02-09 Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA055571A MA55571A (fr) 2015-02-10 2016-02-09 Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA055571A MA55571A (fr) 2015-02-10 2016-02-09 Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Country Status (32)

Country Link
US (3) US10898482B2 (fr)
EP (2) EP3949954A1 (fr)
JP (3) JP6796588B2 (fr)
KR (1) KR20170110145A (fr)
CN (2) CN113209102A (fr)
AU (3) AU2016218000B2 (fr)
BR (1) BR112017017009B1 (fr)
CA (1) CA2976356A1 (fr)
CL (1) CL2017002022A1 (fr)
CO (1) CO2017008862A2 (fr)
CR (1) CR20170411A (fr)
CY (1) CY1124432T1 (fr)
DK (1) DK3256109T3 (fr)
ES (1) ES2883829T3 (fr)
HR (1) HRP20211244T1 (fr)
HU (1) HUE056761T2 (fr)
IL (3) IL310469A (fr)
JO (2) JOP20200201A1 (fr)
LT (1) LT3256109T (fr)
MA (2) MA41496B1 (fr)
MX (2) MX2017010287A (fr)
MY (1) MY196599A (fr)
NI (1) NI201700101A (fr)
NZ (1) NZ734516A (fr)
PH (1) PH12017501421A1 (fr)
PL (1) PL3256109T3 (fr)
RS (1) RS62221B1 (fr)
SG (2) SG11201706472RA (fr)
SI (1) SI3256109T1 (fr)
TW (1) TWI719960B (fr)
UA (1) UA123767C2 (fr)
WO (1) WO2016128411A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SI3353177T1 (sl) 2015-09-23 2020-08-31 Janssen Pharmaceutica Nv Triciklični heterocikli za zdravljenje raka
EP3353164B1 (fr) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. 1,4-benzodiazepines bi-heteroaryl substituees et leurs utilisations pour le traitement du cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
PT3576740T (pt) * 2017-12-20 2023-08-18 Janssen Pharmaceutica Nv Tratamento de cancro
IL295514A (en) * 2020-02-12 2022-10-01 Janssen Pharmaceutica Nv fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle-invasive bladder cancer
TW202333720A (zh) 2021-10-12 2023-09-01 美商塔里斯生物醫學有限責任公司 用於膀胱內施用的厄達替尼調配物及系統
WO2023159216A1 (fr) 2022-02-18 2023-08-24 Taris Biomedical Llc Formulations d'erdafitinib et systèmes osmotiques pour administration intravésicale
WO2023195022A1 (fr) * 2022-04-07 2023-10-12 Natco Pharma Limited Compositions pharmaceutiques stables comprenant de l'erdafitinib

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0698015A1 (fr) 1993-05-14 1996-02-28 Genentech, Inc. Preparation de n-cyanodithioimino-carbonates et de 3-mercapto-5-amino-1h-1,2,4-triazole
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
JP4130700B2 (ja) 1996-02-26 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗腫瘍剤含有組成物
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AU751188C (en) 1997-05-28 2005-06-30 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
AU1918299A (en) 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP1147094A1 (fr) 1999-01-15 2001-10-24 Novo Nordisk A/S Agonistes non peptidiques de glp-1
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
ES2280218T5 (es) 1999-05-05 2010-05-14 Institut Curie Medios de deteccion y tratamiento de patologias asociadas a fgfr3.
SK3542002A3 (en) 1999-09-15 2003-04-01 Warner Lambert Co Pteridinones as kinase inhibitors
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (fr) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives
US20030235628A1 (en) 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
WO2003051833A2 (fr) 2001-12-18 2003-06-26 Merck & Co., Inc. Modulateurs pyrazole a substitution heteroaryle du recepteur 5 metabotropique de glutamate
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
HU229477B1 (en) 2001-12-24 2014-01-28 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
JP2003213463A (ja) 2002-01-17 2003-07-30 Sumitomo Chem Co Ltd 金属腐食防止剤および洗浄液
JP4394960B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
US7074534B2 (en) 2002-07-10 2006-07-11 E. I. Du Pont De Nemours And Company Polymeric charge transport compositions and electronic devices made with such compositions
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP4560483B2 (ja) 2002-10-03 2010-10-13 ターゲジェン インコーポレーティッド 血管静態化物質およびそれらの使用法
JPWO2004037293A1 (ja) 2002-10-22 2006-02-23 大日本住友製薬株式会社 安定化組成物
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
EP1620413A2 (fr) 2003-04-30 2006-02-01 Cytokinetics, Inc. Composes, compositions et procedes
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
MXPA05012645A (es) 2003-05-23 2006-02-08 Zentaris Gmbh Piridopirazinas novedosas y su uso como moduladores de cinasa.
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
WO2005007099A2 (fr) 2003-07-10 2005-01-27 Imclone Systems Incorporated Inhibiteurs de la pkb utilises comme agents antitumoraux
AU2004259000A1 (en) 2003-07-21 2005-02-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for PPAR
CN1829709A (zh) 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
PT1673092E (pt) 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
US20060188568A1 (en) 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
WO2005054201A1 (fr) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp)
WO2005054231A1 (fr) 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrimidines de pyrazolyle et d'imidazolyle
CA2548374C (fr) 2003-12-23 2014-05-27 Astex Therapeutics Limited Derives de pyrazole servant de modulateurs de proteine kinase
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
CN101048388A (zh) 2004-08-31 2007-10-03 阿斯利康(瑞典)有限公司 喹唑啉酮衍生物及其作为B－Raf抑制剂的用途
KR20080075235A (ko) 2004-10-14 2008-08-14 에프. 호프만-라 로슈 아게 Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논
CN101080396A (zh) 2004-10-15 2007-11-28 阿斯利康(瑞典)有限公司 作为B－Raf抑制剂的喹喔啉
EP1659175A1 (fr) 2004-11-18 2006-05-24 Institut Curie Altérations des kératoses séborrhéiques et applications dérivées
KR20070118069A (ko) 2004-12-09 2007-12-13 인시스 테라퓨틱스, 인코포레이티드 실온에서 안정한 드로나비놀 제형
PL1830869T3 (pl) 2004-12-24 2013-11-29 Novartis Ag Sposób leczenia lub profilaktyki
WO2006085335A2 (fr) 2005-01-03 2006-08-17 Lupin Limited Composition pharmaceutique de substances labiles acides
US8278290B2 (en) 2005-02-14 2012-10-02 Biononics Limited Tubulin polymerisation inhibitors
WO2006092430A1 (fr) 2005-03-03 2006-09-08 Universität des Saarlandes Inhibiteurs selectifs de synthases de corticoides humaines
EP1881986A2 (fr) 2005-05-12 2008-01-30 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
NZ563236A (en) 2005-05-13 2010-12-24 Topotarget Uk Ltd Pharmaceutical formulations of N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, aka PXD-101, and arginine
WO2006124944A1 (fr) 2005-05-18 2006-11-23 Wyeth Inhibiteurs de 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile de la tpl2 kinase et procedes de fabrication et d'utilisation de ceux-ci
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
BRPI0615233A2 (pt) 2005-08-26 2011-05-10 Serono Lab derivados de pirazina e uso dos mesmos como inibidores p13k
CA2623768C (fr) 2005-10-07 2016-04-12 Exelixis, Inc. Derives de n-(3-amino-quinoxalin-2-yl) -sulfonamide et leur utilisation comme inhibiteurs de phosphatidylinositol 3-kinase
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (fr) 2005-11-11 2007-05-30 Zentaris GmbH Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal
CN1966500B (zh) 2005-11-17 2011-03-30 中国科学院上海药物研究所 一类喹喔啉类衍生物、制法及用途
US20090247576A1 (en) 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
MX2008008277A (es) 2005-12-21 2009-03-04 Janssen Pharmaceutica Nv Triazolopiridazinas como moduladores de tirosina cinasa.
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2007125405A2 (fr) 2006-05-01 2007-11-08 Pfizer Products Inc. Composés hétérocycliques 2-amino-substitués à cycles fusionnés
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
US20100234347A1 (en) 2006-05-24 2010-09-16 Boehringer Ingelheim Internationl Gmbh Substituted Pteridines substituted with a Four-Membered Heterocycle
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
AU2007271187A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine H4 receptor
WO2008021389A2 (fr) 2006-08-16 2008-02-21 Exelixis, Inc. Procédés d'utilisation de modulateurs pi3k etmek
CN101600714B (zh) 2006-11-10 2013-08-21 百时美施贵宝公司 吡咯并吡啶激酶抑制剂
JP2008127446A (ja) 2006-11-20 2008-06-05 Canon Inc １，５−ナフチリジン化合物及び有機発光素子
MX2009006466A (es) 2006-12-13 2009-06-26 Schering Corp Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2008080001A2 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et procédés pour la modulation de kinases et indications pour celle-ci
CN101652352A (zh) 2006-12-22 2010-02-17 诺瓦提斯公司 用于抑制pdk1的喹唑啉类
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
WO2008109369A2 (fr) 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
EP1990342A1 (fr) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Dérivés de pyridopyrazine, processus de fabrication et utilisations correspondantes
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
WO2008150827A1 (fr) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Dérivés de naphtyridine en tant qu'inhibiteurs de p13 kinase
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
US8461209B2 (en) 2007-06-20 2013-06-11 Mitsubishi Tanabe Pharma Corporation Malonic acid sulfonamide derivative and pharmaceutical use thereof
JP5548123B2 (ja) 2007-06-21 2014-07-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ６−｛ジフルオロ［６−（１−メチル−１Ｈ−ピラゾル−４−イル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］メチル｝キノリンの多形および水和物の形態、塩、ならびに製造方法
JP2010532758A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 組み合わせ抗癌療法
JP5298128B2 (ja) 2007-08-08 2013-09-25 グラクソスミスクライン エルエルシー 癌の治療用のＩＧＦ−１Ｒ阻害剤としての２−［（２−｛フェニルアミノ｝−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）アミノ］ベンズアミド誘導体
WO2009021083A1 (fr) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Dérivés des quinoxalines utilisés comme inhibiteurs des pi3-kinases
WO2009019518A1 (fr) 2007-08-09 2009-02-12 Astrazeneca Ab Composés de pyrimidine ayant un effet inhibiteur du fgfr
WO2013173485A1 (fr) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Détection de cancers de la vessie
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
CA2704599C (fr) 2007-11-16 2015-05-12 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines et 4-pyrazolyl-n-heteroarylpyrimidin-2-amines en tant qu'inhibiteurs de janus kinase
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
WO2009137378A2 (fr) 2008-05-05 2009-11-12 Schering Corporation Administration séquentielle d’agents de chimiothérapie pour le traitement du cancer
CN102036963B (zh) 2008-05-23 2013-08-21 诺瓦提斯公司 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物
CA2743419C (fr) 2008-11-15 2017-02-14 Rib-X Pharmaceuticals, Inc. Compositions antimicrobiennes
EP2356116A1 (fr) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
CA2750047A1 (fr) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Nouveaux antibiotiques bicycliques
JP2012516847A (ja) 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
DK2440545T3 (da) 2009-06-12 2019-07-22 Abivax Forbindelser, der er anvendelige til behandling af cancer
AU2010289397B2 (en) 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
WO2011026579A1 (fr) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Aminoquinoxalines substituées servant d'inhibiteurs de tyrosine-thréonine kinases
CN104666272A (zh) 2009-09-18 2015-06-03 赛诺菲 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (fr) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Nouveaux dérivés de naphtyridine et l'utilisation associée en tant qu'inhibiteurs de kinase
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US9096590B2 (en) 2010-05-24 2015-08-04 Intellikine Llc Substituted benzoxazoles as PI3 kinase inhibitors
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
AP2013007043A0 (en) 2011-01-31 2013-08-31 Novartis Ag Novel heterocyclic derivatives
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
WO2012118492A1 (fr) 2011-03-01 2012-09-07 Array Biopharma Inc. Sulfonamides hétérocycliques en tant qu'inhibiteurs de raf
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
ES2725790T3 (es) 2011-08-26 2019-09-27 Neupharma Inc Algunas entidades químicas, composiciones, y métodos
AU2012308238B2 (en) 2011-09-14 2017-05-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
EP2761300A4 (fr) 2011-09-27 2015-12-02 Univ Michigan Fusions de gènes récurrentes dans le cancer du sein
EP2763994A4 (fr) 2011-10-04 2015-08-26 Gilead Calistoga Llc Nouveaux inhibiteurs de quinoxaline de la voie pi3k
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013061305A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Nouveaux dérivés de purine et utilisation de ceux-ci dans le traitement d'une maladie
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (fr) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3
CN104379740B (zh) 2012-03-08 2019-05-14 安斯泰来制药株式会社 新型fgfr3融合体
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JPWO2014007369A1 (ja) 2012-07-05 2016-06-02 国立研究開発法人国立がん研究センター Ｆｇｆｒ２融合遺伝子
BR112015000203A2 (pt) 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
KR102132149B1 (ko) 2012-07-24 2020-07-09 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 그의 방법
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
CN104487087A (zh) 2012-07-27 2015-04-01 基因泰克公司 治疗fgfr3相关疾患的方法
JP6117222B2 (ja) 2012-09-27 2017-04-19 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CA2890194A1 (fr) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Sels d'amine de laquinimod
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9777333B2 (en) 2013-04-05 2017-10-03 Life Technologies Corporation Gene fusion
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3004380A2 (fr) 2013-05-27 2016-04-13 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Nouvelles translocations dans le cancer du poumon
WO2014201111A1 (fr) 2013-06-14 2014-12-18 The Brigham And Women's Hospital, Inc. Traitement de maladies et de troubles associés à une hyperactivité de mtor
WO2014198337A1 (fr) 2013-06-14 2014-12-18 Synthon B.V. Compositions pharmaceutiques stables et hydrosolubles comprenant du pémétrexed
EP3019628A4 (fr) 2013-07-12 2017-05-10 The Regents Of The University Of Michigan Fusions de gènes récurrentes dans le cancer
EP3027623A4 (fr) 2013-08-02 2017-03-01 Ignyta, Inc. Méthodes de traitement de divers cancers utilisant un inhibiteur axl/cmet seul ou en association avec d'autres agents
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MX2017010595A (es) 2015-02-19 2018-11-12 Bioclin Therapeutics Inc Métodos, composiciones, y equipos para tratamiento de cáncer.
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN105030777B (zh) 2015-07-14 2017-07-21 中国人民解放军第三军医大学第三附属医院 增强alk‑tki疗效、延缓其耐药的复合物及其制剂
CN105147687A (zh) 2015-09-28 2015-12-16 青岛华之草医药科技有限公司 一种治疗白血病的药物达沙替尼组合物胶囊
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
SG11201706472RA (en) 2017-09-28
JOP20200201A1 (ar) 2017-06-16
MX2017010287A (es) 2018-02-09
MA55571A (fr) 2022-02-09
US20240000778A1 (en) 2024-01-04
KR20170110145A (ko) 2017-10-10
JP2021038241A (ja) 2021-03-11
UA123767C2 (uk) 2021-06-02
SG10202000734YA (en) 2020-03-30
CL2017002022A1 (es) 2018-02-16
SI3256109T1 (sl) 2021-11-30
IL253700A0 (en) 2017-09-28
TW201630608A (zh) 2016-09-01
EP3949954A1 (fr) 2022-02-09
AU2020250263A1 (en) 2020-11-05
EP3256109A1 (fr) 2017-12-20
PL3256109T3 (pl) 2021-11-15
CA2976356A1 (fr) 2016-08-18
AU2016218000A1 (en) 2017-08-31
NI201700101A (es) 2018-01-02
MA41496B1 (fr) 2021-09-30
JP2018505193A (ja) 2018-02-22
NZ734516A (en) 2024-03-22
PH12017501421A1 (en) 2018-01-15
BR112017017009B1 (pt) 2023-10-24
TW202123939A (zh) 2021-07-01
MX2021004110A (es) 2021-06-15
LT3256109T (lt) 2021-08-25
DK3256109T3 (da) 2021-08-09
JP6796588B2 (ja) 2020-12-09
CY1124432T1 (el) 2022-07-22
IL281024A (en) 2021-04-29
CN107427511A (zh) 2017-12-01
US10898482B2 (en) 2021-01-26
ES2883829T3 (es) 2021-12-09
MY196599A (en) 2023-04-20
CN113209102A (zh) 2021-08-06
JP2023011758A (ja) 2023-01-24
RS62221B1 (sr) 2021-09-30
AU2022291429A1 (en) 2023-02-02
CR20170411A (es) 2017-11-07
HRP20211244T1 (hr) 2021-11-12
AU2016218000B2 (en) 2020-07-09
US20180021332A1 (en) 2018-01-25
IL253700B (en) 2021-03-25
TWI719960B (zh) 2021-03-01
WO2016128411A1 (fr) 2016-08-18
EP3256109B1 (fr) 2021-07-14
CO2017008862A2 (es) 2018-02-20
IL310469A (en) 2024-03-01
BR112017017009A2 (pt) 2018-04-10
HUE056761T2 (hu) 2022-03-28
JO3695B1 (ar) 2020-08-27
US20210169877A1 (en) 2021-06-10
CN107427511B (zh) 2020-11-03
US11684620B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
MA41496A (fr) Compositions pharmaceutiques comprenant la n-(3,5-diméthoxyphényl)-n'-(1-méthyléthyl)-n-[3-(1-méthyl-1h-pyrazol-4-yl)quinoxalin-6-yl]éthane-1,2-diamine
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
NO2022023I1 (no) Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dih ydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof
IL240030B (en) History of n-[(1-cyanoethyl)phenyl]-2-aza-bicyclo[1.2.2]heptane-3-carboxamide and pharmaceutical preparations containing them
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
ZA201804387B (en) Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
EP3551612A4 (fr) Procédé de préparation de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate et ses polymorphes
IL248785B (en) Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents
MA55015A (fr) Formulations pharmaceutiques
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
DK4023651T3 (da) Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme
MA54095A (fr) Formulations pharmaceutiques aqueuses
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
BR112017014295A2 (pt) composição farmacêutica.
ITUA20161610A1 (it) Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
PT3256109T (pt) Composições farmacêuticas compreendendo n-(3,5-dimetoxifenil)-n¿-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina
MA54904A (fr) Compositions pharmaceutiques comprenant du méloxicam
MA51826A (fr) Compositions pharmaceutiques comprenant de la teixobactine
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
DK3153163T3 (da) Farmaceutisk forbindelse der omfatter 13 glycerider, formulering og anvendelse deraf
TH1701004487A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบด้วย เอ็น-(3,5-ไดเมท็อกซีฟีนิล)-เอ็น'-(1 -เมทิลเอทิล) -เอ็น-[3-(1 -เมทิล- 1 เอช-ไพราซอล-4-อิล)ควิโนซาลิน-6-อิล]อีเทน-1 ,2-ไดเอมีน
HK1254918A1 (zh) Etar抗體，其藥物組合物及其應用
EP3712149C0 (fr) Composé dérivé de benzamide, son procédé de préparation et composition pharmaceutique pour le traitement ou la prévention d'une maladie inflammatoire le contenant en tant qu'ingrédient actif